Clinical Trials Logo

Chronic B-Lymphocytic Leukemia clinical trials

View clinical trials related to Chronic B-Lymphocytic Leukemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00558181 Completed - Clinical trials for Chronic B-Lymphocytic Leukemia

High-dose Methylprednisolone and Rituximab in High Risk B-CLL

LT-CLL-001
Start date: September 2007
Phase: Phase 2
Study type: Interventional

Studies have shown that both high-dose Methylprednisolone and Rituximab used as single agents are effective in relapsed and refractory B-CLL. Methylprednisolone acts independently of p53 apoptosis pathway. The combination of both drugs may improve response and outcome in previously treated high-risk B-CLL patients. Study Objectives Primary: To determine the clinical benefit of high-dose Methylprednisolone and Rituximab in previously treated high-risk B-CLL patients in terms of clinical and flowcytometric response rate. Secondary: To determine progression free and overall survival. To characterize the safety profile of high-dose Methylprednisolone and Rituximab.